Purpose Sotatercept, an activin signalling inhibitor approved in March 2024 for pulmonary arterial hypertension (PAH), ...
Q25 Gross Profit +12% to $114 million; FY 2025 Gross Profit +14% to $446 million4Q25 Income from Operations +9% to $22 million; Adjusted EBITDA ...
Prescription digital therapeutics (PDTs) are FDA-regulated tools that deliver evidence-based interventions via software, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback